FOR THE NEXT GENERATION OF PHYSICIANS
← All USMLE guides
IMMUNOLOGY

Biologic drugs and monoclonal antibodies.

Infliximab, rituximab, trastuzumab, checkpoint inhibitors and other therapeutic antibodies with their targets and risks.

Antibody drug names end in -mab. Learn the target, the use and the major risk.

Common targets

  • TNF-alpha: infliximab, adalimumab, etanercept (latent TB reactivation; screen before starting).
  • CD20: rituximab (B cell lymphoma, rheumatoid arthritis; hepatitis B reactivation).
  • HER2: trastuzumab (cardiotoxicity).
  • VEGF: bevacizumab (impaired wound healing, hemorrhage).
  • EGFR: cetuximab (rash).
  • IgE: omalizumab.
  • IL-6 receptor: tocilizumab.
  • RANKL: denosumab.
  • PCSK9: evolocumab.

Checkpoint inhibitors

Block CTLA-4 (ipilimumab) or PD-1 and PD-L1 (nivolumab, pembrolizumab) and release T cells against tumors. Adverse effects are immune related: colitis, pneumonitis, hepatitis, thyroid and adrenal disease.

Safety

Biologics raise infection risk. Check hepatitis B and tuberculosis status first; avoid live vaccines.

Keep going in immunology

Related on USMLE WEB

Frequently asked questions

What must be checked before anti-TNF therapy?

Latent tuberculosis.

Which antibody blocks PD-1?

Nivolumab or pembrolizumab.